An interventional study of adapted physical activity in Inflammatory Bowel Disease (IBD) and Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis), sponsored by Raincy Montfermeil Hospital Group. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Raincy Montfermeil Hospital Group · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 239 studies in Colitis, Ulcerative with a site in France — 45 open to participants now, 78 under way, 27 of them phase 3. Colitis, Ulcerative · France.
Among the 239 studies in Colitis, Ulcerative with a site in France, this one is the 148th largest by planned enrollment of the 184 interventional ones that give a count, is one of 18 that started in 2025, is one of 35 with no phase, reaches primary completion later than 10 of the 77 other live ones, and was the 221st registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →45 of the 239 studies in Colitis, Ulcerative with a site in France are open now. Recruiting first, the newest first:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18+
Palisade Bio · Sites in France, United States, Canada and 9 more countries
Ages 18–75
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages up to 17
Pfizer · Sites in France, United States, Australia and 7 more countries
Ages 2–11
Janssen Research & Development, LLC · Sites in France, United States, Argentina and 30 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
239 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 71 · Phase 3 73 · Phase 4 14
First in 2003; this study’s year is marked. 18 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is close to the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 196 across the 184 interventional studies, 360 across the 55 observational. Of the 151 that completed or were terminated, 71 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
149 of 239 have an industry lead sponsor. The 10 most frequent:
Raincy Montfermeil Hospital Group is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Raincy Montfermeil Hospital Group has 1 study filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
21 of the studies in Colitis, Ulcerative with a site in France that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 21 to your calendar (.ics) → With an account.
Among the 239 studies in Colitis, Ulcerative with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Inflammatory Bowel Disease (IBD) is a chronic relapsing condition that affects the gastrointestinal tract and is increasingly diagnosed in adolescents and young adults. Although anti-TNFα therapies are effective in reducing disease activity and improving quality of life, they are frequently associated with side effects such as fatigue, weight gain, and joint pain, which may be mitigated by regular physical activity.
Emerging evidence suggests that light to moderate physical activity may help reduce systemic and intestinal inflammation and improve IBD-related outcomes. However, access to structured physical activity programs remains limited, and personal or professional constraints may hinder participation.
This pilot study aims to assess the feasibility and impact of a remotely delivered Adapted Physical Activity (APA) program on the quality of life of patients with Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. This study evaluates the effects of a 12-weeks remote APA intervention on quality of life as the primary outcome.
Secondary objectives include assessing changes in anxiety and depression, fatigue levels, IBD activity, and smoking behavior. The findings from this study may inform the development of scalable, non-pharmacological strategies to support symptom management and well-being in individuals with IBD.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
This study's planned enrollment of 72 is close to the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Browse Colitis, Ulcerative studies →Raincy Montfermeil Hospital Group is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Compared within Colitis, Ulcerative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
High levels of physical activity as defined by the International Physical Activity Questionnaire (IPAQ):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
There is no comparator group at this stage of the research. Patient data will be compared before and after participation in the Adapted Physical Activity (APA) program.
Procedure: adapted physical activity
Comparative before-and-after study over a 3-month period of remote Adapted Physical Activity (APA) delivered through the MOOV+ application
Impact of a Remote Adapted Physical Activity Program Delivered via the MOOV+ Application on Quality of Life in Patients With Inflammatory Bowel Disease: A Pilot Before-and-After Study
Change in total Inflammatory Bowel Disease Questionnaire (IBDQ-32) score between baseline and the end of the program at Month 3 (M3)
Time frame: From baseline (Month 0) to Month 3
evaluate the effect of the program on the different subdomains of health-related quality of life, including bowel symptoms, systemic symptoms, emotional function, and social function
Variation in the four IBDQ-32 subscale scores between baseline (Month 0) and the end of the program (Month 3)
Time frame: From baseline (Month 0) to Month 3
Assess the feasibility of the Remote Adapted Physical Activity Program
Variation of participation rate (number of enrolled patients / number of eligible patients)
Time frame: From baseline (Month 0) to Month 3
Assess the feasibility of the of the Remote Adapted Physical Activity Program
Adherence to the program measured by session attendance rate (sessions attended / sessions scheduled) and dropout rate (number and reasons for early withdrawal).
Time frame: From baseline (Month 0) to Month 3
impact of APA on psychological status
HADS score
Time frame: From baseline (Month 0) to Month 3
impact of APA on fatigue level
FACIT fatigue score
Time frame: From baseline (Month 0) to Month 3
Impact of APA on IBD activity_ crohn's disease
variation of Harvey-Bradshaw Index (HBI)
Time frame: From baseline (Month 0) to Month 3
Impact of APA on IBD activity_ ulcerative colitis
variation of partial mayo score
Time frame: From baseline (Month 0) to Month 3
evaluation of Persistence of physical activity
International Physical Activity Questionnaire (IPAQ )
Time frame: From baseline (Month 0) to Month 3
Change in Biological Markers of Disease Activity (CRP and Fecal Calprotectin)
The impact of Adapted Physical Activity (APA) on biological disease activity will be assessed through changes in C-reactive protein (CRP) levels and fecal calprotectin concentrations
Time frame: From baseline (Month 0) to Month 3
Evaluation of satisfaction level assessed using a 5-point Likert scale.
Evaluation of Satisfaction with a Remote Adapted Physical Activity Program Delivered via MOOV+ (from "1:Very dissatisfied" to "5 : very satisfied")
Time frame: month 3
Started Sep 2025 (actual). Primary completion is estimated for Oct 2025, 1 month after the start.
Of 228 non-industry interventional studies with no phase under Colitis, Ulcerative, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 1 month is below that.
Counting every sponsor, half of 239 studies reached it within 34 months; a quarter within 15 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Raincy Montfermeil Hospital Group